The case for & against
Bull & Bear analysis
Bullish
Arbutus Biopharma (NASDAQ: ABUS) is a biotechnology company primarily focused on developing innovative therapies for chronic hepatitis B virus (HBV) infections. Positioned within the biopharmaceutical sector, the company is engaged in advanced research targeting various modalities, including RNA interference (RNAi) therapies and PD-L1 modulators aimed at achieving a functional cure. Its strategic focus on addressing significant unmet medical needs places it in a competitive landscape, particularly as over 250 million individuals live with chronic HBV globally.
Bull says
- ↑Phase IIa: 33% of patients achieved undetectable hepatitis B surface antigen
- ↑$131 M cash funds operations into Q4 2026
- ↑High 13F ownership signals strong institutional interest
- ↑Combination therapy goal of ≥20% functional cure rate
- ↑Strong profitability factors and low leverage risk
- ↑Innovative RNAi pipeline may shift market perception
Bear says
- ↓2024 net cash burn of $63–67 M pressures $131 M cash balance
- ↓Negative analyst revisions weigh on earnings expectations
- ↓40% workforce reduction risks slowing discovery efforts
- ↓Ongoing IP litigation with Moderna/Pfizer may divert resources
- ↓Competes in crowded HBV market with sub-10% established cure rates
- ↓Weak earnings yield and elevated stock volatility
Investment themes with ABUS
Biotech↓ -3.20%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Earnings Call · Q3 2023 · Mgmt. Guidance
Updated 07-14-2026neutral
Transcript signals
Bull points
- remain committed to our goal of developing a functional cure for patients with chronic hepatitis B virus by advancing the development of our clinical assets that can be combined to create a curative treatment regimen.
- believe we're well-suited to address this need with our team's extensive expertise in virology and with Imdusiran, which is one of the most advanced RNAi therapeutics in development.
- look forward to reporting these data at ASLD.
Bear points
- difficult decision to streamline our organization by reducing our workforce by 24%
- $145 million of cash, cash equivalents and investments
- $184 million as of December 31, 2022
Read full transcript analysis ›